Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ligand Pharmaceuticals (LGND) Receivables (2016 - 2025)

Historic Receivables for Ligand Pharmaceuticals (LGND) over the last 16 years, with Q3 2025 value amounting to $57.6 million.

  • Ligand Pharmaceuticals' Receivables rose 6772.54% to $57.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $57.6 million, marking a year-over-year increase of 6772.54%. This contributed to the annual value of $38.4 million for FY2024, which is 1658.41% up from last year.
  • Per Ligand Pharmaceuticals' latest filing, its Receivables stood at $57.6 million for Q3 2025, which was up 6772.54% from $41.3 million recorded in Q2 2025.
  • Ligand Pharmaceuticals' 5-year Receivables high stood at $85.5 million for Q4 2021, and its period low was $28.0 million during Q2 2023.
  • Its 5-year average for Receivables is $45.5 million, with a median of $38.5 million in 2025.
  • Its Receivables has fluctuated over the past 5 years, first surged by 9550.86% in 2021, then tumbled by 6439.68% in 2022.
  • Ligand Pharmaceuticals' Receivables (Quarter) stood at $85.5 million in 2021, then tumbled by 64.4% to $30.4 million in 2022, then grew by 8.19% to $32.9 million in 2023, then increased by 16.58% to $38.4 million in 2024, then surged by 49.99% to $57.6 million in 2025.
  • Its Receivables was $57.6 million in Q3 2025, compared to $41.3 million in Q2 2025 and $38.5 million in Q1 2025.